Citadel Advisors
BLCM

Citadel Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Citadel Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,590
Closed -$98K – 9959
2018
Q3 		$98K Buy
+1,590
New +$108K ﹤0.01% 8586
2018
Q2 		– Sell
-1,340
Closed -$88K – 9434
2018
Q1 		$88K Sell
1,340
-960
-42% -$72.5K ﹤0.01% 7754
2017
Q4 		$193K Buy
2,300
+810
+54% +$79.4K ﹤0.01% 7134
2017
Q3 		$172K Buy
1,490
+430
+41% +$45.2K ﹤0.01% 6791
2017
Q2 		$124K Buy
1,060
+30
+3% +$3.72K ﹤0.01% 6831
2017
Q1 		$127K Sell
1,030
-950
-48% -$124K ﹤0.01% 6768
2016
Q4 		$270K Buy
1,980
+630
+47% +$112K ﹤0.01% 5825
2016
Q3 		$269K Buy
1,350
+350
+35% +$60.3K ﹤0.01% 5863
2016
Q2 		$130K Sell
1,000
-1,140
-53% -$127K ﹤0.01% 6084
2016
Q1 		$200K Buy
2,140
+1,530
+251% +$167K ﹤0.01% 5645
2015
Q4 		$124K Sell
610
-470
-44% -$84.1K ﹤0.01% 6450
2015
Q3 		$157K Buy
1,080
+820
+315% +$151K ﹤0.01% 6459
2015
Q2 		$55K Buy
260
+160
+160% +$39.2K ﹤0.01% 7593
2015
Q1 		$23K Buy
+100
New +$24.2K ﹤0.01% 7830

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's BLCM Position: Q3 2022 in Review

Citadel Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2022, closing a stake of 11,386 shares — an estimated $13K sold.

Citadel Advisors first reported a position in BLCM in Q4 2014 and held it in 22 quarters. The position peaked at $9.56M in Q2 2015. 28 funds tracked by Wall St. Rank hold BLCM as of Q3 2022.

  • Citadel Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 11,386 Bellicum Pharmaceuticals, Inc. shares in Q3 2022, an estimated $13K.
  • Citadel Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 22 quarters.
  • Citadel Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $9.56M in Q2 2015.
  • 28 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.